Results 271 to 280 of about 380,564 (307)
Some of the next articles are maybe not open access.

Acute Treatment of Ischemic Stroke

Neurologic Clinics, 2022
Ischemic stroke affects 2.5% of the population of the United States and is the leading cause of disability. This article outlines the evidence to support intravenous thrombolysis with alteplase and tenecteplase, thrombolysis in the setting of DWI/flair mismatch, endovascular treatment in the 6-hour and 6- to 24-hour window, and the use of telemedicine ...
Stephanie, Lyden, Jana, Wold
openaire   +2 more sources

Acute ischemic stroke in adolescents

Neurology, 2020
Adolescence represents a transition period between childhood and adulthood, and only limited information exists about stroke characteristics in this population. Our aim was to describe the clinical and neuroradiologic features, etiologies, initial management, and outcome of ischemic stroke in adolescents.This retrospective cohort study evaluated all ...
Thomas Rambaud   +14 more
openaire   +2 more sources

Management of Acute Ischemic Stroke

Seminars in Respiratory and Critical Care Medicine, 2002
Prior to 1995 no proven therapy existed for acute ischemic stroke. In 1996 the U.S. Food and Drug Administration approved the use of intravenous rt-PA in acute stroke based largely on the results of a two-part trial sponsored by the National Institutes of Health and National Institute of Neurological Disorders and Stroke (NIH/NINDS).
openaire   +2 more sources

Management of Acute Ischemic Stroke

The American Journal of Medicine, 2019
The treatment of acute ischemic stroke includes both intravenous (IV) thrombolysis and mechanical thrombectomy. Important advances regarding both treatment modalities have occurred recently that all physicians who see patients at risk for or who have had a stroke should be aware of.
Yunyun, Xiong   +2 more
openaire   +2 more sources

Treatment of acute ischemic stroke

Drugs of Today, 1998
Acute ischemic stroke now is being treated as a medical emergency. The success of the use of tissue plasminogen activator (t-PA) within 3 hours of onset of stroke serves as an impetus for an approach that emphasizes prompt recognition, rapid transportation to a medical center, speedy evaluation and urgent treatment.
H P, Adams, E C, Leira
openaire   +2 more sources

Cyclosporine in acute ischemic stroke

Neurology, 2015
We examined whether IV administration of cyclosporine in combination with thrombolysis might reduce cerebral infarct size.Patients aged 18 to 85 years, presenting with an anterior-circulation stroke and eligible for thrombolytic therapy, were enrolled in this multicenter, single-blinded, controlled trial.
Nighoghossian, N.   +30 more
openaire   +3 more sources

Acute ischemic stroke therapy

Expert Review of Cardiovascular Therapy, 2010
Data from the European Cooperative Acute Stroke Study (ECASS) III trial demonstrated that tissue plasminogen activator given up to 4.5 h after stroke onset improves outcome and treatment guidelines support its use during this time window. Intra-arterial therapy with tissue plasminogen activator or devices is commonly used at large tertiary centers up ...
Henninger, Nils   +2 more
openaire   +3 more sources

Acute Ischemic Stroke and Infections

Journal of Stroke and Cerebrovascular Diseases, 2011
We present an overview of multiple infections in relation to acute ischemic stroke and the therapeutic options available. Conditions that are a direct cause of stroke (infectious endocarditis, meningoencephalitides, and human immunodeficiency virus infection), the pathophysiologic mechanism responsible for stroke, and treatment dilemmas are presented ...
Catalina C, Ionita   +5 more
openaire   +2 more sources

Neuroprotection in acute ischemic stroke.

Acta neurologica Belgica, 2005
Neuroprotection of patients with acute ischemic stroke should start at the scene and continue in the ambulance with the assessment and treatment of the airway, breathing, circulation, body temperature, and blood glucose. The key goal in eligible patients should be fast vessel recanalization with intravenous recombinant tissue-type plasminogen activator
De Keyser, Jacques   +6 more
openaire   +2 more sources

Immunothrombosis in Acute Ischemic Stroke

Stroke
Ischemic stroke is one of the leading causes of disability and mortality worldwide. Thrombosis is the main pathological process of stroke and is therefore an important therapeutic target in stroke prevention. In recent years, with the development of endovascular treatment and therefore retrieving the thrombus for further investigation, evidence is ...
Yan Wang   +4 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy